Back

T505A variant of ETV5 promotes proliferation of precursor B cells in a mouse model of acute lymphoblastic leukemia

Yi, J.; Wu, M.; Dowling, M. L.; MacKenzie, A. C.; Iansavitchous, J.; DeKoter, R. P.

2024-12-22 immunology
10.1101/2024.12.19.629436 bioRxiv
Show abstract

Precursor B cell acute lymphoblastic leukemia (pre-B-ALL) arises as a result of precursor B cells acquiring driver mutations that lead to arrested differentiation and increased proliferation. Identification of driver mutations and understanding their biological function is critical to understanding pre-B-ALL development and advancing disease treatment. Using a mouse model of pre-B-ALL driven by deletion of genes encoding the related E26-transformation-specific (ETS) transcription factors PU.1 and Spi-B, we performed whole exome sequencing to identify secondary driver mutations. We identified recurrent variants in E26 transformation-specific transcription variant 5 (ETV5) resulting in R392P, V444I, and T505A amino acid changes. We found that the R392P and V444I variants altered the ability of ETV5 to bind to DNA using electrophoretic mobility shift assay. R392P and V444I variants did not activate a Dual-Specificity-Phosphatase 6 (DUSP6) reporter. In contrast, T505A ETV5 could interact with DNA and activate the DUSP6 promoter. To determine biological function, we forced expression of wild type, R392P, V444I, or T505A ETV5 in an interleukin-7-dependent pre-B cell line. Proliferation and apoptosis assays showed that T505A ETV5 conferred a proliferative advantage to pre-B cells. RNA sequencing showed that expression of ETV5 variants significantly altered gene expression in cultured cells. Through gene set enrichment analysis, T505A was suggested to downregulate the p53 pathway and the anti-proliferative protein, B cell translocation gene 2 (encoded by Btg2). In summary, these data suggest that ETV5 mutations play a role in pre-B-ALL by affecting proliferation and cell survival.

Matching journals

The top 10 journals account for 50% of the predicted probability mass.

1
Molecular Immunology
14 papers in training set
Top 0.1%
7.3%
2
Frontiers in Immunology
638 papers in training set
Top 2%
6.8%
3
eLife
5828 papers in training set
Top 16%
6.8%
4
Life Science Alliance
285 papers in training set
Top 0.2%
6.8%
5
iScience
1154 papers in training set
Top 2%
5.5%
6
Journal of Experimental Medicine
119 papers in training set
Top 0.4%
5.5%
7
RNA
189 papers in training set
Top 0.5%
4.1%
8
EMBO Reports
263 papers in training set
Top 1%
4.1%
9
Scientific Reports
3612 papers in training set
Top 38%
2.8%
10
PLOS Pathogens
820 papers in training set
Top 5%
2.7%
50% of probability mass above
11
Cell Reports
1498 papers in training set
Top 18%
2.0%
12
Disease Models & Mechanisms
119 papers in training set
Top 1.0%
1.9%
13
Blood
74 papers in training set
Top 0.7%
1.9%
14
EMBO Molecular Medicine
95 papers in training set
Top 0.7%
1.9%
15
Oncogene
85 papers in training set
Top 1.0%
1.7%
16
Biochemical and Biophysical Research Communications
84 papers in training set
Top 1%
1.7%
17
Frontiers in Genetics
230 papers in training set
Top 3%
1.5%
18
The EMBO Journal
309 papers in training set
Top 5%
1.1%
19
Biology Open
156 papers in training set
Top 3%
1.0%
20
Nature Communications
5641 papers in training set
Top 54%
1.0%
21
Cancer Letters
35 papers in training set
Top 1.0%
1.0%
22
Immunogenetics
11 papers in training set
Top 0.1%
0.9%
23
Science Advances
1243 papers in training set
Top 30%
0.9%
24
Leukemia
42 papers in training set
Top 0.7%
0.9%
25
Blood Cancer Journal
14 papers in training set
Top 0.3%
0.9%
26
Nucleic Acids Research
1281 papers in training set
Top 13%
0.9%
27
Cell Reports Medicine
153 papers in training set
Top 4%
0.9%
28
International Journal of Molecular Sciences
494 papers in training set
Top 15%
0.9%
29
The Journal of Immunology
166 papers in training set
Top 2%
0.9%
30
Protein Engineering, Design and Selection
15 papers in training set
Top 0.2%
0.9%